Patents by Inventor John B. Robbins
John B. Robbins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9173932Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: GrantFiled: June 2, 2014Date of Patent: November 3, 2015Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Patent number: 9144604Abstract: Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure: Pr—Sr—O—N?C-Kdo-OS wherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure: wherein R is between 1 and 10 disaccharide repeat units. In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure: ?-L-AltNAcA-3-?-FucNAc4N-4-.Type: GrantFiled: May 5, 2014Date of Patent: September 29, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, National Research Council of CanadaInventors: John B. Robbins, Rachel Schneerson, Joanna Kubler-Kielb, Christopher P. Mocca, Evguenii Vinogradov
-
Patent number: 9096653Abstract: Disclosed are immunogenic conjugates which elicit an immune response to Plasmodium proteins. In particular examples, the Plasmodium proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to Plasmodium in a subject, comprising administering to the subject an immunogenic composition disclosed herein.Type: GrantFiled: April 25, 2013Date of Patent: August 4, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, New York UniversityInventors: Rachel Schneerson, Joanna Kubler-Kielb, John B. Robbins, Fathy Majadly, Christopher P. Mocca, Jerry Keith, Zuzana Biesova, Louis Miller, Ruth Nussenzweig, Darrell T. Liu
-
Publication number: 20150093412Abstract: Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, National Research Council of CanadaInventors: Joanna Kubler-Kielb, Evguenii Vinogradov, Rachel Schneerson, Haijing Hu, Stephen H. Leppla, John B. Robbins
-
Publication number: 20150050314Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.Type: ApplicationFiled: October 29, 2014Publication date: February 19, 2015Applicant: The United States of America as represented by the Secretary, Department of Health and Human ServiceInventors: Rachel Schneerson, Joanna Kubler-Kielb, Yimin Wu, Louis Miller, Fathy Majadly, John B. Robbins
-
Patent number: 8926986Abstract: Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.Type: GrantFiled: June 4, 2013Date of Patent: January 6, 2015Assignees: National Research Council of Canada, The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Joanna Kubler-Kielb, Evguenii Vinogradov, Rachel Schneerson, Haijing Hu, Stephen H. Leppla, John B. Robbins
-
Patent number: 8900599Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.Type: GrantFiled: January 25, 2013Date of Patent: December 2, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rachel Schneerson, Joanna Kubler-Kielb, Yimin Wu, Louis Miller, Fathy Majadly, John B. Robbins
-
Patent number: 8852605Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: GrantFiled: April 3, 2007Date of Patent: October 7, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Publication number: 20140287476Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: ApplicationFiled: June 2, 2014Publication date: September 25, 2014Inventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Publication number: 20140242666Abstract: Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure: Pr-Sr-O—N?C-Kdo-OS wherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure: wherein R is between 1 and 10 disaccharide repeat units. In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure: ?-L-AltNAcA-3-?-FucNAc4N-4-.Type: ApplicationFiled: May 5, 2014Publication date: August 28, 2014Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Ser, National Research Council of CanadaInventors: John B. Robbins, Rachel Schneerson, Joanna Kubler-Kielb, Christopher P. Mocca, Evguenii Vinogradov
-
Publication number: 20140205622Abstract: Disclosed are immunogenic conjugates having the general formula: M2e-Cys-S—CH2—C(O)—NH—CH2—CH2-C(O—)NH-Lys-Pr, were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.Type: ApplicationFiled: January 16, 2014Publication date: July 24, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Mark A. Miller, Rachel Schneerson, Joanna Kubler-Kielb, John B. Robbins, Zuzana Biesova, Jerry Keith
-
Patent number: 8747863Abstract: Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure: Pr—Sr—O—N?C-Kdo-OS wherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure: wherein R is between 1 and 10 disaccharide repeat units. In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure: ?-L-AltNAcA-3-?-FucNAc4N-4-.Type: GrantFiled: August 14, 2009Date of Patent: June 10, 2014Assignees: The United States of America, as represented by the Secretary of the Department of Health and Human Services, National Research Council of CanadaInventors: John B. Robbins, Rachel Schneerson, Joanna Kubler-Kielb, Christopher P. Mocca, Evguenii Vinogradov
-
Patent number: 8703150Abstract: The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: GrantFiled: September 23, 2011Date of Patent: April 22, 2014Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Stephen H. Leppla, Rachel Schneerson, John B. Robbins
-
Patent number: 8658180Abstract: Disclosed are immunogenic conjugates having the general formula: M2e-Cys-S—CH2—C(O)—NH—CH2—CH2-C(O—)NH-Lys-Pr, were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.Type: GrantFiled: August 14, 2009Date of Patent: February 25, 2014Inventors: Mark A. Miller, Rachel Schneerson, Joanna Kubler-Kielb, John B. Robbins, Zuzana Biesova, Jerry Keith
-
Publication number: 20130273097Abstract: Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.Type: ApplicationFiled: June 4, 2013Publication date: October 17, 2013Inventors: Joanna Kubler-Kielb, Evguenii Vinogradov, Rachel Schneerson, Haijing Hu, Stephen H. Leppla, John B. Robbins
-
Patent number: 8481048Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: GrantFiled: October 20, 2009Date of Patent: July 9, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of HealthInventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
-
Patent number: 8444996Abstract: Disclosed are immunogenic conjugates which elicit an immune response to Plasmodium proteins. In particular examples, the Plasmodium proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to Plasmodium in a subject, comprising administering to the subject an immunogenic composition disclosed herein.Type: GrantFiled: October 1, 2009Date of Patent: May 21, 2013Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, New York UniversityInventors: Rachel Schneerson, Joanna Kubler-Kielb, John B. Robbins, Fathy Majadly, Christopher P. Mocca, Jerry Keith, Zuzana Biesova, Louis Miller, Ruth Nussenzweig, Darrell T. Liu
-
Patent number: 8394387Abstract: The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: GrantFiled: July 31, 2007Date of Patent: March 12, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Stephen H. Leppla, Mary Jo Rosovitz, John B. Robbins, Rachel Schneerson, S. Dana Hsu, Joseph Shiloach, Delia M. Ramirez
-
Publication number: 20130058967Abstract: The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: ApplicationFiled: July 31, 2007Publication date: March 7, 2013Inventors: Stephen H. Leppla, Mary Jo Rosovitz, John B. Robbins, Rachel Schneerson, S. Dana Hsu, Joseph Shiloach, Delia M. Ramirez
-
Patent number: 8383133Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.Type: GrantFiled: October 15, 2007Date of Patent: February 26, 2013Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Rachel Schneerson, Joanna Kubler-Kielb, Yimin Wu, Louis Miller, Fathy D. Majadly, John B. Robbins